Kanadevia Corp
Kanadevia Corp (HIZOF) Financial Performance & Income Statement Overview
Analyze Kanadevia Corp (HIZOF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Kanadevia Corp (HIZOF) Income Statement & Financial Overview
Analyze Kanadevia Corp’s HIZOF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $197.09B | $143.47B | $148.40B | $121.56B |
| Cost of Revenue | $154.94B | $114.19B | $124.98B | $102.22B |
| Gross Profit | $42.15B | $29.28B | $23.42B | $19.34B |
| Gross Profit Ratio | $0.21 | $0.20 | $0.16 | $0.16 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $24.95B | $22.70B | $19.38B | $20.22B |
| Operating Expenses | $24.95B | $22.70B | $19.38B | $20.22B |
| Total Costs & Expenses | $179.89B | $136.89B | $144.36B | $122.44B |
| Interest Income | $0.00 | $226.00M | $439.00M | $283.00M |
| Interest Expense | $0.00 | $299.00M | $308.00M | $222.00M |
| Depreciation & Amortization | $3.33B | $3.70B | $3.16B | $878.00M |
| EBITDA | $18.19B | $9.45B | $7.21B | -$962.00M |
| EBITDA Ratio | $0.09 | $0.07 | $0.05 | -$0.008 |
| Operating Income | $17.20B | $6.58B | $4.04B | -$878.00M |
| Operating Income Ratio | $0.09 | $0.05 | $0.03 | -$0.007 |
| Other Income/Expenses (Net) | -$2.37B | $1.63B | -$1.34B | -$1.18B |
| Income Before Tax | $14.83B | $8.21B | $2.70B | -$2.06B |
| Income Before Tax Ratio | $0.08 | $0.06 | $0.02 | -$0.02 |
| Income Tax Expense | -$1.94B | $1.64B | $983.00M | $712.00M |
| Net Income | $16.71B | $6.53B | $1.67B | -$2.81B |
| Net Income Ratio | $0.08 | $0.05 | $0.01 | -$0.02 |
| EPS | $99.35 | $38.84 | $9.95 | -$16.69 |
| Diluted EPS | $99.35 | $38.84 | $9.95 | -$16.69 |
| Weighted Avg Shares Outstanding | $168.19M | $168.19M | $168.19M | $168.52M |
| Weighted Avg Shares Outstanding (Diluted) | $168.19M | $168.19M | $168.19M | $168.52M |
Over the past four quarters, Kanadevia Corp demonstrated steady revenue growth, increasing from $121.56B in Q1 2024 to $197.09B in Q4 2024. Operating income reached $17.20B in Q4 2024, maintaining a consistent 9% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $18.19B, reflecting operational efficiency. Net income rose to $16.71B, with EPS at $99.35. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan